MBX Biosciences

The lead candidate is MBX 2109, a once-weekly injectable parathyroid hormone peptide prodrug for chronic hypoparathyroidism — a rare endocrine condition where the body produces insufficient parathyroid hormone, leading to dangerously low calcium levels. MBX 2109 uses a cleavable prodrug structure to extend the hormone's half-life, enabling weekly dosing. The drug entered a Phase 3 registrational trial in November 2024, and Phase 2 data showed that 93% of patients achieved normalized serum calcium at 24 weeks.

MBX Biosciences completed its initial public offering on the Nasdaq Global Select Market in September 2024 under the ticker MBX, raising gross proceeds of $163.2 million. Prior to the IPO, the company raised over $100 million in private venture funding from investors including Frazier Life Sciences, OrbiMed, and Wellington Management. The firm's most recent private round was a $63.5 million Series C in April 2024 (per Fierce Biotech, April 2024). As a publicly listed operating company, MBX uses equity capital and potential future revenues rather than a fund-based capital pool.

Kent Hawryluk co-founded the company and serves as President and CEO; he previously spent over a decade in business development and commercial roles at Eli Lilly and Endocyte, where he worked on radiopharmaceutical and peptide-based drugs. Dr. Richard S. Levy serves as Chief Medical Officer, bringing experience from endocrine drug development programs at multiple biotech firms. The company's board and scientific team include veterans of endocrine and metabolic drug development at Eli Lilly, Novo Nordisk, and Amgen.

MBX applies two proprietary technology strategies: a peptide half-life extension platform that improves pharmacokinetics and receptor selectivity, and a prodrug system that enables long-acting hormone therapies to be dosed once-weekly rather than daily. These technologies are designed specifically for endocrine and metabolic disorders — a therapeutic area where existing treatments are often decades-old replacements or symptomatic therapies rather than disease-modifying biologics. The firm's entire pipeline is built on these peptide-engineering advances applied to well-characterized hormonal pathways.

Yes. MBX 1416 targets post-bariatric hypoglycemia — a serious complication of gastric bypass surgery causing dangerously low blood sugar — and completed a Phase 1 trial in early 2024. The company's preclinical pipeline includes an oral GLP-1 receptor antagonist for hyperinsulinemic hypoglycemia and additional programs focused on obesity comorbidities. MBX's public disclosures indicate it intends to advance these programs toward clinical trials over the next two years while prioritizing the Phase 3 hypoparathyroidism study.

MBX holds exclusive worldwide commercial rights to its clinical-stage assets under composition-of-matter patents that extend into the 2040s. The company's patent strategy covers the peptide sequences, prodrug structures, and manufacturing methods for its lead candidates. As an independent, publicly traded biotech, MBX does not share IP rights with academic institutions or pharmaceutical partners on its core programs, which provides full control over development and commercialization timelines.

MBX Biosciences operates with approximately 30 employees, predominantly based at its research and headquarters facility in Carmel, Indiana — a location that draws on the region's concentration of pharmaceutical talent from Eli Lilly and the broader Midwest biotech corridor. The company is incorporated in Delaware. As a clinical-stage organization, the majority of its team focuses on research, clinical operations, and regulatory affairs, with additional functions supporting its public-company reporting obligations.